Who are Optimal Medical treatment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Giapreza, Benicar, Micardis, Atacand, Teveten, Avapro.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/optimal-medical-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Optimal Medical treatment — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimal Medical treatment (Optimal Medical treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor. Area: Cardiovascular.

marketed ACE inhibitor Angiotensin II receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Optimal Medical treatment (Optimal Medical treatment) — Seung-Jung Park. Optimal Medical treatment works by inhibiting the renin-angiotensin system to lower blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Optimal Medical treatment TARGET	Optimal Medical treatment	Seung-Jung Park	marketed	ACE inhibitor	Angiotensin II receptor
Giapreza	ANGIOTENSIN II	La Jolla Pharma	marketed	Vasoconstrictor [EPC]	Type-2 angiotensin II receptor, Type-1 angiotensin II receptor, Type-1 angiotensin II receptor	2017-01-01
Benicar	OLMESARTAN MEDOXOMIL	Cosette	marketed	Thiazide Diuretic [EPC]	Type-1 angiotensin II receptor	2002-01-01
Micardis	TELMISARTAN	Boehringer Ingelheim	marketed	Angiotensin 2 Receptor Blocker [EPC]	Type-2 angiotensin II receptor	1998-01-01
Atacand	CANDESARTAN CILEXETIL	ANI Pharmaceuticals	marketed	Angiotensin 2 Receptor Blocker	Type-1 angiotensin II receptor	1998-01-01
Teveten	EPROSARTAN	AbbVie	marketed	Angiotensin 2 Receptor Blocker	Type-1 angiotensin II receptor	1997-01-01
Avapro	IRBESARTAN	Sanofi	marketed	Angiotensin 2 Receptor Blocker [EPC]	Type-1 angiotensin II receptor	1997-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor class)

Boryung Pharmaceutical Co., Ltd · 5 drugs in this class
Bioprojet · 2 drugs in this class
Ain Shams University · 2 drugs in this class
Ahn-Gook Pharmaceuticals Co.,Ltd · 1 drug in this class
Beijing Tide Pharmaceutical Co., Ltd · 1 drug in this class
Children's Hospital of Fudan University · 1 drug in this class
Ache Laboratorios Farmaceuticos S.A. · 1 drug in this class
Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
Ethicare GmbH · 1 drug in this class
Ace Cells Lab Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Optimal Medical treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/optimal-medical-treatment. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab